Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis
Sponsor: Novartis Pharmaceuticals
This PHASE3 trial investigates Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis and is currently completed. Novartis Pharmaceuticals leads this study, which shows 20 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
20 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Sep 2022 [monthly]
Completed PHASE3
▶ Show 15 earlier versions
-
May 2021 — Apr 2022 [monthly]
Completed PHASE3
-
Feb 2021 — May 2021 [monthly]
Completed PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Oct 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .